- Type
- not stated
- Format
- Structured longitudinal clinical records — patient and episode attributes, laboratory and drug-concentration measurements, dose administration events, model-predicted exposures, and coded outcomes and adverse events — integrated from electronic health records, laboratory systems and flat files, and exposed both as analytic tables supporting pharmacokinetic and pharmacodynamic modelling and simulation and as a natural-language query layer, so the archive also carries a corpus of plain-language clinical analytic questions bound to their resolved queries
- Volume
- No vendor-stated totals. Structurally implies 1-20M dosing episodes across deployed institutions to date, each carrying a dense multi-point record — patient attributes, laboratory panel, measured concentrations, recommended and administered doses, and outcome — so roughly 20-150M discrete clinical observations. The scarcest component, and the one worth pricing, is measured drug-concentration-plus-dose tuples: an estimated 1-10M pairs, since these require therapeutic drug monitoring to have been ordered and represent the true pharmacokinetic ground truth. All figures inferred from institutional scale and dosing cadence, not published.
- Users
- Client-side: an estimated 20-100 health-system institutions and roughly 2,000-15,000 named clinician and pharmacist users, inferred from about $3.6M revenue at enterprise health-system contract values across a 33-person company. Data subjects are the asset and are far more numerous: every dosed patient episode at every deployed institution contributes records, so patient volume is an order of magnitude above user count. The analytics product is explicitly designed for clinicians, department leads, directors and executives, indicating multi-role deployment per institution.
- History
- 10 years
- Update frequency
- not stated
- Growth
- Active and research-intensive, still early commercial stage — the firm holds a patented process for continuous model retraining, runs a published scientific-publication programme, and has extended beyond provider-facing clinical tools into a dedicated life-sciences line for pharmacokinetic and pharmacodynamic modelling and simulation plus clinical-trial use, which indicates product-line expansion rather than maintenance. At a 33-person headcount with roughly $12.8M raised and roughly $3.6M revenue, it remains venture-stage and commercially early, so growth is capability-driven rather than scale-driven.
- Launched
- ~2015-2017 for the precision-dosing product. The company record carries an organizational identifier from mid-2015, and the presence of issued patents, a peer-reviewed publication record and an established health-system install base implies several years of prior development and deployment. The life-sciences product line is materially newer, an estimated 2021-2023, reflecting a deliberate extension from provider tooling into pharma-facing capability. No founding or launch year is stated on the retrieved page.
- Delivery
- not stated
- Entity mapping
- not stated
- Sample
- not stated
- Point-in-time
- not stated
- Licence
- not stated